Kaycee Inds. (504084)

FairStock Score: 30/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• High capital efficiency: ROE of 22.86% and ROCE of 30.55%
• Strong recent growth: sales up 21.74% and profit up 26.80%
• Good Piotroski F-Score of 7/9 suggests solid recent financial health

Concerns

• Stretched valuation: P/E of 44.60, P/B of 19.49, and PEG of 1.84
• FairStock Score of 25/100 labels the stock as risky
• Very small scale: latest quarterly sales are ₹14 Cr and net profit is ₹1 Cr against a ₹550 Cr market cap
• Negligible dividend yield of 0.24% while the stock sits near its 52-week high

AI Analysis

Let me look at Kaycee Inds. through the lens I have used for decades: is this a wonderful business at a fair price, or a fair business at a wonderful price? The numbers tell me the first part is questionable. The company earns a strong return on equity of 22.86% and ROCE of 30.55%, which suggests efficient capital deployment. Growth is impressive -- sales up 21.74% and profits up 26.80%. The Piotroski F-Score of 7/9 indicates a reasonably healthy financial setup. Yet at ₹1,697.60, I am paying ₹44.60 for every rupee of earnings and 19.49 times book value. That valuation leaves no cushion. Graham taught me that paying a high price for even a good business turns the odds against you. Here, the PEG ratio of 1.84 tells me the market has already priced in the growth -- and probably more. The latest quarter is tiny: sales of ₹14 crore and net profit of just ₹1 crore. That is a very small revenue base to justify a ₹550 crore market cap. With dividend yield of 0.24%, the shareholder receives negligible cash while waiting for growth. The stock sits at the top of its 52-week range, having tripled from ₹632.30; that is the kind of move that makes me cautious rather than enthusiastic. The FairStock score of 25/100, labelled risky, aligns with my reading: excellent recent performance, but price and scale are dangerous. I would not write off the business -- F-Score of 7 is good -- but I would demand a much lower price or clear evidence that the small quarterly figures can compound substantially. At this price, the risk-reward is unfavourable. Better to watch from the sidelines.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer